Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Staphylococcus aureus With Reduced Susceptibility to Vancomycin—United States, 1997

Staphylococcus aureus With Reduced Susceptibility to Vancomycin—United States, 1997 STAPHYLOCOCCUS aureus is one of the most common causes of both hospital- and community-acquired infections worldwide, and the antimicrobial agent vancomycin has been used to treat many S. aureus infections, particularly those caused by methicillinresistant S. aureus (MRSA). In 1996, the first documented case of infection caused by a strain of S. aureus with intermediate levels of resistance to vancomycin (VISA; minimum inhibitory concentration [MIC]=8 μg/mL) was reported from Japan.1 This report describes the first isolation of VISA from a patient in the United States, which may be an early warning that S. aureus strains with full resistance to vancomycin will emerge. In July 1997, VISA-associated peritonitis was diagnosed in a patient who was being treated with long-term ambulatory peritoneal dialysis. During January 1996-June 1997, the patient had been treated with multiple courses of both intraperitoneal and intravenous vancomycin for repeated episodes of MRSA-associated peritonitis. The http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Staphylococcus aureus With Reduced Susceptibility to Vancomycin—United States, 1997

JAMA , Volume 278 (11) – Sep 17, 1997
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/staphylococcus-aureus-with-reduced-susceptibility-to-vancomycin-united-kc0HD509vM

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1997 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1997.03550110029014
Publisher site
See Article on Publisher Site

Abstract

STAPHYLOCOCCUS aureus is one of the most common causes of both hospital- and community-acquired infections worldwide, and the antimicrobial agent vancomycin has been used to treat many S. aureus infections, particularly those caused by methicillinresistant S. aureus (MRSA). In 1996, the first documented case of infection caused by a strain of S. aureus with intermediate levels of resistance to vancomycin (VISA; minimum inhibitory concentration [MIC]=8 μg/mL) was reported from Japan.1 This report describes the first isolation of VISA from a patient in the United States, which may be an early warning that S. aureus strains with full resistance to vancomycin will emerge. In July 1997, VISA-associated peritonitis was diagnosed in a patient who was being treated with long-term ambulatory peritoneal dialysis. During January 1996-June 1997, the patient had been treated with multiple courses of both intraperitoneal and intravenous vancomycin for repeated episodes of MRSA-associated peritonitis. The

Journal

JAMA – American Medical Association

Published: Sep 17, 1997

There are no references for this article.